Equillium Receives Australian Regulatory Clearance for EQ504 Clinical Trial

Equillium has received Australian regulatory clearance to initiate a first-in-human clinical trial for its EQ504 drug. The randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EQ504 in healthy subjects. Dosing is expected to begin by early November 2026, with topline Phase 1 proof-of-mechanism data anticipated about six months after study initiation.